dexmedetomidine + midazolam

Dexmedetomidine + midazolam is a combination of two sedative agents frequently used for procedural and perioperative sedation in both pediatric and adult patients. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that induces sedation, anxiolysis, and analgesia primarily by acting on receptors in the locus ceruleus of the brainstem, with minimal respiratory depression. Midazolam is a short-acting benzodiazepine that acts as a positive allosteric modulator at the gamma-aminobutyric acid type A (GABA-A) receptor, producing sedative, anxiolytic, amnestic, and anticonvulsant effects. The combination leverages complementary mechanisms to achieve effective sedation with potentially improved safety profiles—such as higher sedation success rates and lower incidence of nausea/vomiting compared to other regimens—especially in pediatric procedural settings[1][2]. This regimen may also help maintain hemodynamic stability during anesthesia or procedures[2].

Other names

intranasal dexmedetomidine and oral midazolam